PCN70 Healthcare Resource Utilization and Costs Among Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Anaplastic Lymphoma Kinase (ALK) Inhibitors

In the phase III ALEX study, alectinib demonstrated superior progression-free survival over crizotinib for treatment-naïve patients with ALK+ NSCLC. This study aims to evaluate health resource utilization (HRU) and costs receiving or as first ALK inhibitor (ALKi). retrospective observational identified ≥ 18 years old lung cancer (ICD-9: 162, ICD-10: C34) their ALKi between 1/1/2015 6/30/2019 from PharMetrics Plus claims database. Patients were required have continuous medical pharmacy enrollment 6 months before 12 after initiation date (index date) no prior treatment during pre-index. HRU per-patient-per-month (PPPM) (reported in 2019 USD) post-index summarized by index ALKi. A multivariate generalized linear model log-link gamma distribution was applied estimate total cost of care, adjusting baseline characteristics. The included 53 124 patients. post-index, less likely any emergency department (ED) inpatient visits compared (ED: 24.5% vs 40.3%, p=0.044; inpatient: 22.6% 41.3%, p=0.019). Although similar (unadjusted PPPM cost: $12,749 $12,825, p=0.933), care lower than $18,461 $21,307, p=0.069]. After characteristics, 19.5% (adjusted $15,536 $19,303, p=0.005). this had approximately 20% mean adjusted crizotinib. real-world economic evidence supplements clinical benefits supporting use NSCLC